ESTRADIOL AND NORETHINDRONE ACETATE TABLETS DIN 02563177
Health Canada record
| Active ingredient(s) | ESTRADIOL HEMIHYDRATE 1 MG; NORETHINDRONE ACETATE 0.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03FA01 NORETHISTERONE AND ESTROGEN |
| Original market date | |
| Current status date | 05-Jun-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novast Laboratories Ltd — licence , not currently licensed, last inspection rating C (2023-07-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESTRADIOL HEMIHYDRATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02568829 | ACTIFEMME | ORB PHARMA- DIVISION OF ODAN LABORATORIES LTD. | Tablet | ESTRADIOL HEMIHYDRATE 1 MG; NORETHINDRONE ACETATE 0.5 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37672 | 2026-06-05 | Supplement to an Abbreviated New Drug Submission (SANDS) | Administrative: Change in product name |
| 36470 | 2025-12-02 | Abbreviated New Drug Submission (ANDS) |
International API supply for ESTRADIOL HEMIHYDRATE
8 valid EDQM Certificates of Suitability from 8 holders. 6 active FDA Drug Master Files.
Request a quote for ESTRADIOL AND NORETHINDRONE ACETATE TABLETS